Harbour BioMed has formed an “initial strategic” collaboration with WuXi Biologics to develop clinical trial supplies of Harbour’s leading HCAb antibody. Harbour, headquartered in the Boston area with a development facility in Shanghai, launched 18 months ago to develop IO and immunology therapies. Harbour BioMed was funded with $50 million in startup capital and included an existing Dutch discovery company, Harbour Antibodies BV. Harbour and WuXi Biologics will develop the HCAb antibody candidate for China and other global markets.
Source: China Biotoday
